INmune Bio, Inc. logo

INmune Bio, Inc.

NASDAQ:INMB

Overview | Financials
Company Name INmune Bio, Inc.
Symbol INMB
Currency USD
Price 5.88
Market Cap 116,320,512
Dividend Yield 0%
52-week-range 5.799 - 14.74
Industry Biotechnology
Sector Healthcare
CEO Dr. Raymond Joseph Tesi M.D.
Website https://www.inmunebio.com

An error occurred while fetching data.

About INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory

Related Stocks

Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc.

ATOS

1.33 USD

FONAR Corporation logo

FONAR Corporation

FONR

16.49 USD

Societal CDMO, Inc. logo

Societal CDMO, Inc.

SCTL

1.1 USD

Omega Therapeutics, Inc. logo

Omega Therapeutics, Inc.

OMGA

1.22 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

14.5 USD

Financials

Numbers are in millions USD

Numbers are in millions USD